Gene Variants That May Enhance the Effectiveness of Non-Hodgkin Lymphoma Therapy: Genomic and Bioinformatics Approaches
Abstract
Background/Aim: Non-Hodgkin lymphoma (NHL) is a cancer of the lymphatic system with a high incidence rate globally. Patient responses to therapies such as chemotherapy and immunotherapy often vary, which is thought to be related to individual genetic differences. The development of genomic and bioinformatic technologies allows the identification of gene variants that play a role in the effectiveness of therapy, thus opening up opportunities for personalised treatment of NHL. This study aimed to identify genetic variants that have the potential to improve the effectiveness of therapy in NHL patients.
Methods: This study used a bioinformatics approach to analyse genetic and clinical data available in several database sources, including PharmGKB, Haploreg v4.2, GTEx Portal and Ensembl.
Results: This study identified two significant genetic variants, rs396991 in the FCGR3A gene and rs3957357 in the GSTA1 gene, that play a role in improving the effectiveness of NHL therapy. The rs396991 variant showed increased affinity to IgG1 and effectiveness of antibody-dependent cellular cytotoxicity (ADCC) mechanism in rituximab therapy. Meanwhile, the rs3957357 variant in GSTA1 was associated with better event-free survival in patients receiving R-CHOP chemotherapy. High expression of FCGR3A gene in immune tissues and GSTA1 gene in liver also reinforced its biological role in therapy response.
Conclusions: Genetic variations in FCGR3A (rs396991) and GSTA1 (rs3957357) have potential as predictive biomarkers of R-CHOP therapy effectiveness in NHL patients. These findings support the application of genetic analysis as a basis for more personalised and effective therapeutic strategies in the treatment of NHL.
References
Jamil A, Mukkamalla SKR. Lymphoma. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. [Cited: 14-Apr-2025]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560826/.
Irham LM, Amukti DP, Adikusuma W, Singh D, Chong R, Pranata S, et al. Trends in drug repurposing for chronic hepatitis-B infection: bibliometric-basedapproach1990-2024. In: BIO Web of Conferences. EDP Sciences; 2025.
Candelaria M, Dueñas-Gonzalez A. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Ther Adv Hematol. 2021;12:2040620721989579. doi: 10.1177/2040620721989579.
Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–8. doi: 10.1182/blood.2019002729.
Lavacchi D, Landini I, Perrone G, Roviello G, Mini E, Nobili S. Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge. Pharmacol Ther. 2022;229(107924):107924. doi: 10.1016/j.pharmthera.2021.107924.
Edina BC, Rinaldi I. Effectiveness of bendamustine-rituximab compared to R-CHOP/R-CVP as a first-line treatment of indolent Non-Hodgkin’s Lymphoma or mantle-cell lymphoma. Acta Med Indones. 2022;54(2):316–23. PMID: 35818660.
McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene. 2006;25(11):1639–48. doi: 10.1038/sj.onc.1209373.
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116(3):496–526. doi: 10.1016/j.pharmthera.2007.09.004.
Kim DH, Jung H Du, Kim JG, Lee JJ, Yang DH, Park YH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108(8):2720–5. doi: 10.1182/blood-2006-01-009480.
Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112(24):3754–62. doi: 10.1161/CIRCULATIONAHA.105.576850.
Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006;112(2):457–73. doi: 10.1016/j.pharmthera.2006.04.009.
Amukti DP, Wazni AR, Irham LM, Sulistyani N, Ma’ruf M, Adikusuma W, et al. Identifying pathogenic variants associated with Alzeimer by integrating genomic databases and bioinformatics approaches. E3S Web of Conferences. EDP Sciences; 2024:501:01021.
Amukti DP, Irham LM, Surono S, El Khair R, Adikusuma W, Satria R, et al. Atherosclerosis research in the genomic era: global trends from 1983 to 2024. Bulg Cardiol. 2024 Dec 31;30(4):40–8. doi: 10.3897/bgcardio.30.e143367.
Amukti DP, Irham LM, Surono S, Adikusuma W, Chong R, El Khair R, et al. Genomic variants and epidemiology of atherosclerosis – worldwide correlation analysis and utilization of atherosclerosis gene variants for identification of drug target candidates with bioinformatics approach. Bulg Cardiol. 2024 Dec 31;30(4):108–20. doi: 10.3897/bgcardio.30.e145391.
Gumelar G, Ulfa MM, Amukti DP, Irham LM, Yuliani S, Adikusuma W, et al. Harnessing genomic and bioinformatic data to broaden understanding of leukaemia across continents. Scr Med. 2024 Nov 1;55(6):717–25. doi: 10.5937/scriptamed55-51720.
Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563–72. doi: 10.1002/cpt.2350.
Li L, Huang Z, Du K, Liu X, Li C, Wang D, et al. Integrative pan-cancer analysis confirmed that FCGR3A is a candidate biomarker associated with tumor immunity. Front Pharmacol. 2022;13:900699. doi: 10.3389/fphar.2022.900699.
Irham LM, Amukti DP, Adikusuma W, Singh D, Chong R, Basyuni M, et al. Applied of bioinformatics in drug discovery and drug development: bioinformatic analysis 1996-2024. In: BIO Web of Conferences. EDP Sciences; 2025.
Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 2016;76(1):7–9. doi: 10.1158/0008-5472.CAN-15-3143.
Nimmerjahn F, Ravetch J V. Fcgamma receptors: old friends and new family members. Immunity. 2006;24(1):19–28. doi: 10.1016/j.immuni.2005.11.010.
Fc Gamma Receptor/FCGR/FcγR | Sino Biological [Internet]. [Cited: 14-Apr-2025]. Available from: https://www.sinobiological.com/research/fc-receptor/fc-gamma-receptor.
Rougé L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020;367(6483):1224–30. doi: 10.1126/science.aaz9356.
Engelhard M. Anti-CD20 antibody treatment of non-Hodgkin lymphomas. Clin Immunol. 2016;172:101–4. doi: 10.1016/j.clim.2016.08.011.
Makanga DR, Jullien M, David G, Legrand N, Willem C, Dubreuil L, et al. Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. Oncoimmunology. 2021;10(1):1936392. doi: 10.1080/2162402X.2021.1936392.
Miller ML, Finn OJ. Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions. Methods Enzymol. 2020;632:431–56. doi: 10.1016/bs.mie.2019.07.026.
Mlakar V, Curtis PHD, Armengol M, Ythier V, Dupanloup I, Hassine K Ben, et al. The analysis of GSTA1 promoter genetic and functional diversity of human populations. Sci Rep. 2021;11(1):5038. doi: 10.1038/s41598-021-83996-2.
Indrawijaya YY, Artarini AA, Hamijoyo L, Iwo MI. GSTA1 gene polymorphisms are associated with cyclophosphamide effectiveness in lupus nephritis patients: A case-control study in Indonesia. Narra J. 2024;4(3):e1144. doi: 10.52225/narra.v4i3.1144.
Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L, et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia. 2009;23(6):1118–26. doi: 10.1038/leu.2008.398.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).